Earl HM, Hiller L, Vallier AL, Loi S, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019 Jun 6. pii: S0140-6736(19)30650.
PMID: 31178152